Matching articles for "Lynkuet"
Elinzanetant (Lynkuet) for Menopausal Vasomotor Symptoms
The Medical Letter on Drugs and Therapeutics • December 22, 2025; (Issue 1744)
Elinzanetant (Lynkuet – Bayer), a first-in-class
neurokinin 1 (NK1) and neurokinin 3 (NK3) receptor
antagonist, has been approved by the FDA for
treatment of moderate to severe vasomotor symptoms
(VMS)...
Elinzanetant (Lynkuet – Bayer), a first-in-class
neurokinin 1 (NK1) and neurokinin 3 (NK3) receptor
antagonist, has been approved by the FDA for
treatment of moderate to severe vasomotor symptoms
(VMS) due to menopause. Fezolinetant (Veozah), an
NK3 receptor antagonist, was approved for the same
indication in 2023.